Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NIM 1324

X
Drug Profile

NIM 1324

Alternative Names: BT-104; LABP-104; NIM-1324

Latest Information Update: 29 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Landos Biopharma
  • Class Anti-inflammatories; Antirheumatics; Small molecules; Urologics
  • Mechanism of Action Inflammation mediator inhibitors; LANCL2 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis; Systemic lupus erythematosus
  • No development reported Lupus nephritis

Most Recent Events

  • 23 May 2024 Landos Biopharma has been acquired by AbbVie
  • 25 Mar 2024 Pharmacodynamics data from preclinical study in Systemic lupus erythematosus, Rheumatoid arthritis, and Multiple sclerosis released by Landos Biopharma
  • 25 Mar 2024 Landos Biopharma plans a phase II trial for Systemic lupus erythematosus (PO) in second half of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top